whitepaper
Application note: A novel way to expedite antibody discovery
Analyse isotype titer and cell health in one assay...
List view / Grid view
Cell-based assays
article
Streamlining drug discovery assays for cancer and cardiovascular disease
For lead optimisation, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological relevance is driving ongoing growth in cell-based assays.
article
Expert view: How high-content platforms keep pace with the changing face of cell-based drug screening
For the next generation of cell biologists, 3D cell culture and analysis has opened doors to taking applied research one step further.
article
Supporting the progression of phenotypic hits with bioactivity profiling
Bioactivity profiling has been traditionally used to assess the selectivity of new drug candidates in the context of target-based approaches, where pharmacological selectivity is a key requirement.
whitepaper
Whitepaper: Smart cell monitoring
This whitepaper outlines how advances in real-time live-cell monitoring and analysis methods are addressing these changing needs.
webinar
Using bioactivity profiling to support the progression of phenotypic hits
27 April 2018 | By Eurofins Pharma Discovery Services
In this webinar, we discussed a recent case study where a phenotypic screen was performed using poly I:C / IL-4 stimulated human bronchial epithelial cells. This resulted in the identification of 7 representative hits which provided starting points for new drug discovery opportunities.
webinar
in vitro phenotypic assays for Parkinson’s disease
26 April 2018 | By Charles River Laboratories
This webinar highlights cell based assays for Parkinson’s disease that include endpoints such as a-synuclein aggregation and mitophagy readouts.
whitepaper
Application note: CRISPR/Cas9 genome-edited cells express nanoBRET-donor that monitors protein interaction and trafficking
In this application note, BMG Labtech discuss how the Bioluminescence resonance energy transfer (BRET) is a versatile tool to study interactions and trafficking in proteins.
article
Expert view: Addressing the big challenges in cell-based assays
As the drug discovery industry takes on the complex disease states that plague our world, the need for more relevant and timely answers from cell-based assays has become a major challenge.
article
Expert view: Toward physiological relevance in drug discovery and development
Physiologically relevant screening models have become increasingly important in assay development and the screening of drug candidates.
article
Streamlining drug discovery assays for cancer and cardiovascular disease
Declining R&D productivity is a key challenge in the pharmaceutical industry. To increase the success rate of candidate drugs entering the clinical phase, companies must address the early stages of drug discovery.
news
Helpful B cells lend a hand to developing neurons
Researchers at Osaka University have identified an immune cell that promotes the growth of neuron-supporting cells in the developing mouse brain.
product
Molecular Devices launches the ImageXpress Pico system
Cellular imaging acquisition and analysis system at an affordable price point.
webinar
Streamlining drug discovery assays for cancer and cardiovascular disease
1 February 2018 | By PerkinElmer
This webinar discussed a screening assay that recapitulates the activation of ER stress sensor IRE1 and an assay to quantify cell migration phenotypes, as applied to cardiovascular target validation and drug discovery.
whitepaper
Whitepaper: Phenotypic drug discovery with high content screening
Reasons for phenotypic vs. target based drug discovery strategies, challenges of and maximising return of phenotypic assays.
